Search results
Results from the WOW.Com Content Network
Primidone is an anticonvulsant of the barbiturate class; [7] however, its long-term effect in raising the seizure threshold is likely due to its active metabolite, phenobarbital. [10] The drug’s other active metabolite is phenylethylmalonamide (PEMA). Primidone was approved for medical use in the United States in 1954. [7]
Felbamate (marketed under the brand name Felbatol by MedPointe) is an anticonvulsant [2] used in the treatment of epilepsy.It is used to treat partial seizures [3] [4] (with and without generalization) in adults and partial and generalized seizures associated with Lennox–Gastaut syndrome in children.
Valproic acid, and its derivatives such as sodium valproate and divalproex sodium, causes cognitive deficit in the child, with an increased dose causing decreased intelligence quotient and use is associated with adverse neurodevelopmental outcomes (cognitive and behavioral) in children.
Dupuytren's contracture is not listed as a side effect or adverse effect of Primidone by medline.gov. The page's reference Critchley EM, Vakil SD, Hayward HW, Owen VM (May 1976) does show a high incidence of Dupuytren's contracture with phenobarbitone, but a lower incidence (2 of 21) of those taking primidone or phenytoin without phenobarbitone.
Phenobarbital, also known as phenobarbitone or phenobarb, sold under the brand name Luminal among others, is a medication of the barbiturate type. [6] It is recommended by the World Health Organization (WHO) for the treatment of certain types of epilepsy in developing countries . [ 8 ]
In the United States, cenobamate is indicated for the treatment of partial-onset seizures in adults. [3]In the European Union, it is indicated for the adjunctive treatment of focal-onset seizures with or without secondary generalization in adults with epilepsy who have not been adequately controlled despite a history of treatment with at least two anti-epileptic medications.
Methylphenobarbital (), also known as mephobarbital (USAN, JAN) and mephobarbitone (), marketed under brand names such as Mebaral, Mephyltaletten, Phemiton, and Prominal, is a drug which is a barbiturate derivative and is used primarily as an anticonvulsant, [2] but also as a sedative and anxiolytic.
Perampanel, sold under the brand name Fycompa, is an anti-epileptic medication developed by Eisai Co. that is used in addition to other drugs to treat partial seizures and generalized tonic-clonic seizures for people older than twelve years. [8]